Juvenescence, a life sciences company focused on increasing human longevity and treating diseases of aging, has closed $100 million in Series B funding. The investors included Grok Ventures.
Source: Press Release
Juvenescence, a life sciences company focused on increasing human longevity and treating diseases of aging, has closed $100 million in Series B funding. The investors included Grok Ventures.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination